Cas No.: | 2117405-13-5 |
Chemical Name: | 6'-Fluoro-4-(4-methyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,2';3',3'']terpyridine |
Synonyms: | SEN177,SEN 177 |
SMILES: | CN1C(C2CCN(C3=NC(F)=CC=C3C4=CC=CN=C4)CC2)=NN=C1 |
Formula: | C18H19FN6 |
M.Wt: | 338.39 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | SEN177 is an inhibitor of glutaminyl cyclase (QPCT), thereby rescuing the Huntington's disease (HD)-related phenotypes in cell. |
In Vitro: | SEN177 is a Glutaminyl cyclase (QPCT) inhibitor. Glutaminyl cyclase modifies N-terminal glutamine or glutamate residues to N-terminal 5-oxoproline or pyroglutamate (named QPCT). QPCT inhibits mutant huntingtin from forming aggregates, but also reduces aggregation of other aggregate-prone proteins containing polyQ or polyA repeats. SEN177 caused dose-dependent decreases in HTT aggregation by a mechanism that requires QPCT inhibition. SEN177 had in vitro activity against polyglutamine toxicity and was able to reduce aggregates in mammalian cells, primary neurons and in a Drosophila model. |